icd 9 code for supranuclear palsy

What is the ICD 10 code for Bell's palsy?

ICD-10-CM Diagnosis Code G23.1. Progressive supranuclear ophthalmoplegia [Steele-Richardson-Olszewski] 2016 2017 2018 2019 2020 2021 Billable/Specific Code. Applicable To. Progressive supranuclear palsy. ICD-10-CM Diagnosis Code G51.0 [convert to ICD-9-CM] Bell's palsy. Bell's palsy of left face; Bell's palsy of right face; Bells palsy;

What do Parkinson's disease and progressive supranuclear palsy have in common?

The death of brain cells in one of these areas, the substantia nigra, accounts in part for the motor symptoms that PSP and Parkinson's have in common. The hallmark of PSP is the accumulation of abnormal deposits of the protein tau in nerve cells in the brain.

What is the ICD-9 code for diagnosis?

ICD-9-CM 333.0 is a billable medical code that can be used to indicate a diagnosis on a reimbursement claim, however, 333.0 should only be used for claims with a date of service on or before September 30, 2015.

What is the ICD 10 code for Neurologic diagnosis?

G23.1 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2018/2019 edition of ICD-10-CM G23.1 became effective on October 1, 2018. This is the American ICD-10-CM version of G23.1 - other international versions of ICD-10 G23.1 may differ.

What is the ICD 10 code for supranuclear palsy?

ICD-10-CM Code for Progressive supranuclear ophthalmoplegia [Steele-Richardson-Olszewski] G23. 1.

What is G23 1?

G23.1 Progressive supranuclear ophthalmoplegia [Steele-Richardson-Olszewski]

What is supranuclear palsy?

Progressive supranuclear palsy is an uncommon brain disorder that causes serious problems with walking, balance and eye movements, and later with swallowing. The disorder results from deterioration of cells in areas of your brain that control body movement, coordination, thinking and other important functions.

What is supranuclear ophthalmoplegia?

Supranuclear ophthalmoplegia is a condition that affects the movement of the eyes.

What is progressive supranuclear palsy?

Progressive supranuclear palsy (psp) is a rare brain disease. It affects brain cells that control the movement of your eyes.

Why is PSP dangerous?

However, psp is dangerous because it increases your risk of pneumonia and choking from swallowing problems and injuries from falling. Spastic weakness of the muscles innervated by the cranial nerves, i.e., the muscle of the face, pharynx, and tongue, due to bilateral lesions of the corticospinal tract.

What is the degenerative disorder of the central nervous system?

A degenerative disease of the central nervous system characterized by balance difficulties; ocular motility disorders (supranuclear ophthalmoplegia); dysarthria; swallowing difficulties; and axial dystonia. Onset is usually in the fifth decade and disease progression occurs over several years.

Introduction

Progressive supranuclear palsy (PSP) is a rare neurodegenerative movement disorder characterized by motor, behavioral, and cognitive dysfunction ( 1, 2 ).

Materials and Methods

This nested case-control study used data from the IBM MarketScan Commercial and Medicare Supplemental Databases, a large set of US insurance databases containing medical service and prescription drug claims prospectively collected from employer-based commercial and Medicare supplemental health insurance plans.

Results

Of the ~38 million patients in the MarketScan databases with ≥1 month of enrollment time in the database from October 1, 2015 through October 31, 2017, 630 patients met the criteria for PSP.

Discussion

This nested case-control study, in which PSP cases were compared to controls, provides real-world data from the largest cohort of PSP patients in the world reported to date.

Data Availability Statement

The data analyzed in this study is subject to the following licenses/restrictions: The dataset was generated from an administrative claims database for which Biogen holds an in-house license. Requests to access these datasets should be directed to SE ( [email protected] ).

Author Contributions

MJ, LL, HK, and SE conducted or contributed to the statistical analysis. All authors contributed to conception and design of the study, manuscript revision, and read and approved the submitted version.

Funding

This study was sponsored by Biogen. Biogen provided funding to Excel Scientific Solutions for medical writing support in the development of this paper.